Anaesthetic drugs & techniques

Patterns of remimazolam use and recovery after procedural sedation and anaesthesia: a multicentre cohort study

BJA OpenPublished Retrospective cohort study

Authors' conclusion

In this large multicentre cohort, remimazolam was associated with rapid recovery and low rates of serious adverse events across diverse procedural settings and patient acuity levels.

Study context

Population
Patients receiving remimazolam for procedural sedation and anaesthesia in a multisite US academic health system, 1 June 2021 to 29 February 2024
Participants
8,011 patients · 9,431 procedures
Outcome
Patterns of remimazolam use, incl. recovery characteristics (time to return to baseline RASS score and PACU discharge readiness times)
Methodological detailsmulticentre
  • Multicentre

Main finding

As reported in the abstract

Remimazolam use and recovery
GroupValueMedian time to baseline RASSMedian PACU discharge readiness timeProcedures outside the operating room
Remimazolammedian 12 (IQR 8–20) mg13 min (IQR 5-30)30 min (IQR 15-55)70.5%

Remimazolam

Valuemedian 12 (IQR 8–20) mg
Median time to baseline RASS13 min (IQR 5-30)
Median PACU discharge readiness time30 min (IQR 15-55)
Procedures outside the operating room70.5%

Observational data: associations, not effects.

Secondary outcomes

OutcomeAdjusted GMR (95% CI)P value
Flumazenil use vs none in cardioversion cases: PACU discharge readiness time (subgroup)0.83 (0.75–0.93)P < 0.001
Flumazenil use vs none in cardioversion cases: time to baseline RASS (subgroup)0.63 (0.48–0.83)P < 0.001

Remimazolam dose and recovery times

Higher dose associated with longer recovery times, plateau above ≈18 mg
P < 0.001

Safety

Critical events (allergic reactions, cardiorespiratory depression, or death)

Critical events, % of procedures
0.7%
Possible IgE-mediated reactions
4 (0.04%)

Original publication

Patterns of remimazolam use and recovery after procedural sedation and anaesthesia: a multicentre cohort study. BJA Open. Published 2 July 2026. doi:10.1016/j.bjao.2026.100575

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.